Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of neuroblastoma by histopathology OR bone marrow metastases and high urine catecholamine levels~* Disease must meet risk-related treatment guidelines and any of the following International Neuroblastoma Staging System stages:~  * Stage 4 with (any age) OR without (\> 18 months of age of age) MYCN amplification~ * MYCN-amplified other than stage 1~* No evidence of disease (i.e., in complete response/remission or very good partial response/remission) OR disease resistant to standard therapy (i.e., incomplete response in bone marrow)~* No progressive disease or MIBG-avid soft tissue tumor~PATIENT CHARACTERISTICS:~* No existing renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity ≥ grade 3~* No human anti-mouse antibody (HAMA) titer greater than 1,000 Elisa units/mL~* No history of allergy to mouse proteins~* No active life-threatening infection~* Not pregnant~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients have refractory bone marrow disease (Type: EXPERIMENTAL): This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
- patients have no evidence of disease (Type: EXPERIMENTAL): This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.

Based on this trial design, predict the completion outcome and termination type (if applicable).